SG156681A1 - Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure - Google Patents
Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failureInfo
- Publication number
- SG156681A1 SG156681A1 SG200907097-0A SG2009070970A SG156681A1 SG 156681 A1 SG156681 A1 SG 156681A1 SG 2009070970 A SG2009070970 A SG 2009070970A SG 156681 A1 SG156681 A1 SG 156681A1
- Authority
- SG
- Singapore
- Prior art keywords
- remodeling
- ranolazine
- treatment
- heart failure
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62615404P | 2004-11-09 | 2004-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG156681A1 true SG156681A1 (en) | 2009-11-26 |
Family
ID=35892429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200907097-0A SG156681A1 (en) | 2004-11-09 | 2005-11-09 | Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure |
Country Status (15)
Country | Link |
---|---|
US (2) | US20060111361A1 (pt) |
EP (1) | EP1809289A1 (pt) |
JP (1) | JP2008519770A (pt) |
KR (1) | KR20070084063A (pt) |
CN (1) | CN101072562A (pt) |
AU (1) | AU2005304421A1 (pt) |
BR (1) | BRPI0517650A (pt) |
CA (1) | CA2586840A1 (pt) |
IL (1) | IL183056A0 (pt) |
MX (1) | MX2007005367A (pt) |
NO (1) | NO20072934L (pt) |
RU (1) | RU2007121707A (pt) |
SG (1) | SG156681A1 (pt) |
WO (1) | WO2006053161A1 (pt) |
ZA (1) | ZA200703697B (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1505977B1 (en) * | 2002-05-21 | 2014-09-10 | Gilead Sciences, Inc. | Administration of a partial fatty acid oxidation inhibitor such as ranolazine for the treatment of diabetes |
US20090012413A1 (en) * | 2006-09-08 | 2009-01-08 | Sabbah Hani N | Cardiac patterning for improving diastolic function |
US9782258B2 (en) * | 2006-09-08 | 2017-10-10 | The Regents Of The University Of California | Intramyocardial patterning for global cardiac resizing and reshaping |
EP2101775A1 (en) * | 2006-12-21 | 2009-09-23 | Cv Therapeutics, Inc. | Reduction of cardiovascular symptoms |
JP2010518169A (ja) * | 2007-02-13 | 2010-05-27 | ギリアード・パロ・アルト・インコーポレイテッド | 心血管疾患の処置のためのラノラジンの使用 |
US20080248112A1 (en) * | 2007-02-13 | 2008-10-09 | Brent Blackburn | Use of ranolazine for the treatment of coronary microvascular diseases |
US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
JP2010518171A (ja) * | 2007-02-13 | 2010-05-27 | ギリアード・パロ・アルト・インコーポレイテッド | 非冠微小血管疾患の処置のためのラノラジンの使用 |
US20080233191A1 (en) * | 2007-03-22 | 2008-09-25 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
AU2008239681B2 (en) * | 2007-04-11 | 2013-10-03 | Henry Ford Health System | Cardiac repair, resizing and reshaping using the venous system of the heart |
KR20100033490A (ko) * | 2007-05-31 | 2010-03-30 | 질레드 팔로 알토 인코포레이티드 | 상승된 뇌-형 나트륨이뇨 펩티드에 대한 라놀라진 |
US20090012103A1 (en) * | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
US20100292217A1 (en) * | 2009-05-14 | 2010-11-18 | Gilead Palo Alto, Inc. | Ranolazine for the treatment of cns disorders |
JP2011010865A (ja) | 2009-06-30 | 2011-01-20 | Ikaria Holdings Inc | 肺高血圧の臨床的または超音波心臓検査上の証拠を伴う低酸素性呼吸器不全に罹った満期産およびほぼ満期産の新生児を治療する方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0714660B1 (en) * | 1989-06-23 | 2002-09-04 | Syntex (U.S.A.) LLC | Ranolazine and related piperazines for protecting skeletal muscles |
US20030077229A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
WO2001028548A1 (en) * | 1999-10-19 | 2001-04-26 | Texas Heart Institute | Treatment of heart disease with cox-2 inhibitors |
BR0108452A (pt) * | 2000-02-18 | 2003-04-01 | Cv Therapeutics Inc | Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva |
AU2001277938A1 (en) * | 2000-07-21 | 2002-02-05 | Cv Therapeutics, Inc. | Method for treating angina |
US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
-
2005
- 2005-11-09 EP EP05826116A patent/EP1809289A1/en not_active Withdrawn
- 2005-11-09 JP JP2007540416A patent/JP2008519770A/ja not_active Withdrawn
- 2005-11-09 RU RU2007121707/14A patent/RU2007121707A/ru not_active Application Discontinuation
- 2005-11-09 BR BRPI0517650-6A patent/BRPI0517650A/pt not_active IP Right Cessation
- 2005-11-09 CN CNA2005800380175A patent/CN101072562A/zh active Pending
- 2005-11-09 KR KR1020077010435A patent/KR20070084063A/ko not_active Application Discontinuation
- 2005-11-09 SG SG200907097-0A patent/SG156681A1/en unknown
- 2005-11-09 US US11/271,168 patent/US20060111361A1/en not_active Abandoned
- 2005-11-09 CA CA002586840A patent/CA2586840A1/en not_active Abandoned
- 2005-11-09 AU AU2005304421A patent/AU2005304421A1/en not_active Abandoned
- 2005-11-09 WO PCT/US2005/040824 patent/WO2006053161A1/en active Application Filing
- 2005-11-09 MX MX2007005367A patent/MX2007005367A/es unknown
-
2007
- 2007-05-08 IL IL183056A patent/IL183056A0/en unknown
- 2007-05-08 ZA ZA200703697A patent/ZA200703697B/xx unknown
- 2007-06-08 NO NO20072934A patent/NO20072934L/no not_active Application Discontinuation
-
2009
- 2009-02-26 US US12/393,952 patent/US20090176772A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20090176772A1 (en) | 2009-07-09 |
IL183056A0 (en) | 2007-10-31 |
AU2005304421A1 (en) | 2006-05-18 |
ZA200703697B (en) | 2008-09-25 |
CA2586840A1 (en) | 2006-05-18 |
MX2007005367A (es) | 2007-06-18 |
CN101072562A (zh) | 2007-11-14 |
NO20072934L (no) | 2007-08-08 |
EP1809289A1 (en) | 2007-07-25 |
KR20070084063A (ko) | 2007-08-24 |
US20060111361A1 (en) | 2006-05-25 |
WO2006053161A8 (en) | 2006-09-14 |
JP2008519770A (ja) | 2008-06-12 |
BRPI0517650A (pt) | 2008-10-14 |
RU2007121707A (ru) | 2008-12-20 |
WO2006053161A1 (en) | 2006-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG156681A1 (en) | Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure | |
EA200800006A1 (ru) | Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i | |
AP1913A (en) | Substituted benzazoles and use thereof as raf kinase inhibitors | |
WO2009137465A3 (en) | Compositions for treatment or prevention of pathological cardiac remodeling and heart failure | |
NO20065847L (no) | Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase | |
MX2007002311A (es) | Antagonistas del receptor de endotelina a(eta) en combinacion con inhibidores de fosfodiesterasa 5 (pdes) y usos de los mismos. | |
WO2004010937A3 (en) | Method of treating cancer | |
GB0018527D0 (en) | Composition | |
MY150697A (en) | Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha | |
MY140514A (en) | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | |
WO2005094554A3 (en) | Therapeutic agents, methods, and treatments | |
WO2008127594A3 (en) | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
CL2013001136A1 (es) | Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional. | |
SG160425A1 (en) | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | |
ECSP11011030A (es) | Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional. | |
NO20054216L (no) | Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag | |
MA34547B1 (fr) | Traitement d'association pour traiter une infection par le vhc | |
AU2009246603A8 (en) | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction | |
WO2020047352A8 (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
MX2010010334A (es) | Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida. | |
WO2003092606A3 (en) | Cholinesterase inhibitors to prevent injuries caused by chemicals | |
MX2021003845A (es) | Composiciones para reducir el acido urico serico. | |
WO2008016640A3 (en) | Use of poloxamer for the prevention and/or treatment of heart failure | |
MX2021002878A (es) | Inhibidores de cd73 y usos farmaceuticos de los mismos. | |
WO2007041388A3 (en) | Prevention and treatment of hearing disorders |